# A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct06868277/  
OnCo record `nct06868277` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Rilvegostomig and Pembrolizumab in non-small-cell lung cancer, run by AstraZeneca, now recruiting.

## Summary

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT06868277 by AstraZeneca, with 830 participants planned, started 2025-04-10 and due to reach its primary completion in 2030-01-17. Interventions recorded: Rilvegostomig and Pembrolizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06868277
- Phase: 3
- Setting: A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients With PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)
- Sponsor: AstraZeneca
- Enrolled: 830

## Sources

- ClinicalTrials.gov NCT06868277: https://clinicaltrials.gov/study/NCT06868277

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Rilvegostomig](https://onco.cc/drugs/rilvegostomig/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06868277.json